Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Testosterone
Drug ID BADD_D02170
Description Testosterone is a steroid sex hormone indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone antagonizes the androgen receptor to induce gene expression that causes the growth and development of masculine sex organs and secondary sexual characteristics.[A187114,L8983,L8935,L8938,L8986,L8989,L8992,L8995] Testosterone was isolated from samples and also synthesized in 1935.[A186943]
Indications and Usage Testosterone is indicated to treat primary hypogonadism and hypogonadotropic hypogonadism.[L8983,L8935,L8938,L8986,L8989,L8992,L8995]
Marketing Status approved; investigational
ATC Code G03BA03
DrugBank ID DB00624
KEGG ID D00075
MeSH ID D013739
PubChem ID 6013
TTD Drug ID D06XMU
NDC Product Code 0832-1120; 65089-0050; 43598-304; 49884-418; 63629-8455; 63629-9310; 0591-2925; 38779-2936; 43647-568; 43742-1436; 73774-014; 76003-1083; 43742-1242; 0245-0871; 62332-552; 70700-112; 76420-685; 76420-687; 76420-699; 24979-130; 45802-610; 0051-8462; 64380-151; 68180-943; 69097-363; 0591-2363; 0603-7831; 0009-5020; 44132-006; 49452-7658; 64025-0010; 45802-281; 0245-0872; 0023-5992; 63629-2125; 64380-152; 66887-001; 0591-2114; 0591-2924; 0591-2926; 0591-3216; 0832-1121; 51927-0267; 70492-002; 76420-684; 0009-0074; 12875-8248; 22552-0009; 49452-7652; 60592-721; 60870-0251; 16714-967; 17139-562; 63629-2124; 68180-941; 44132-008; 48087-0113; 51552-0029; 42667-5511; 63481-183; 63629-2352; 69238-1013; 0591-3217; 0591-3524; 38779-0163; 38779-2598; 82393-113; 24979-078; 45802-366; 66887-004; 51552-0564; 62991-2150; 76420-686; 16714-969; 45802-754; 49884-510; 62332-488; 69339-158; 0591-2921; 49452-7657; 16714-968; 0023-5990
UNII 3XMK78S47O
Synonyms Testosterone | 17-beta-Hydroxy-4-Androsten-3-one | 17 beta Hydroxy 4 Androsten 3 one | Androtop | Histerone | Sterotate | Sustanon | Androderm | Testoderm | Testolin | Testopel | Testosterone Sulfate | AndroGel | 8-Isotestosterone | 8 Isotestosterone | 17-beta-Hydroxy-8 alpha-4-Androsten-3-one | 17 beta Hydroxy 8 alpha 4 Androsten 3 one | Andropatch | Testim
Chemical Information
Molecular Formula C19H28O2
CAS Registry Number 58-22-0
SMILES CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Neurological symptom17.02.05.0100.000136%-
Prostate cancer16.25.01.001; 21.04.02.0020.001045%-
General symptom08.01.03.0210.000091%-
Abdominal symptom07.01.06.007---
Appetite disorder14.03.01.004; 19.09.01.002---
Breast cancer male16.10.01.002; 21.05.01.0080.000136%-
Breast disorder21.05.04.004---
Cardiac disorder02.11.01.0030.003626%-
Connective tissue disorder10.04.04.026; 15.06.01.006---
Embolism24.01.01.0090.000682%
Infarction24.04.02.0170.000636%-
Infestation11.09.01.001; 23.11.01.002---
Inflammation08.01.05.007; 10.02.01.089---
Intervertebral disc degeneration15.10.01.0020.000245%-
Ischaemia24.04.02.0040.000364%-
Ischaemic stroke17.08.01.018; 24.04.06.0100.003590%-
Malnutrition14.03.02.004---
Mediastinal disorder22.09.03.001---
Mental disorder19.07.01.002---
Motor dysfunction15.05.06.006; 17.01.02.0310.000136%-
Peripheral embolism24.01.02.0050.000182%-
Soft tissue disorder15.03.02.012--
Sudden hearing loss04.02.01.009---
Cardiac valve disease02.07.02.0010.000182%-
Venous thrombosis limb24.01.02.0090.000227%-
Erectile dysfunction19.08.04.001; 21.03.01.007--
Ill-defined disorder08.01.03.049---
Inner ear disorder04.04.02.002---
Polyp08.01.06.010; 16.02.02.005---
Blood disorder01.05.01.004---
The 16th Page    First    Pre   16 17 18 19    Next   Last    Total 19 Pages